The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
Open accessAbstract
Importance: Data sets linking comprehensive genomic profiling (CGP) to clinical outcomes may accelerate precision medicine. Objective: To assess whether a database that combines EHR-derived clinical data with CGP can identify and extend associations in non-small cell lung cancer (NSCLC). Design, Setting, and Participants: Clinical data from EHRs were linked with CGP results for 28 998 patients from 275 US oncology practices. Among 4064 patients with NSCLC, exploratory associations between tumor genomics and patient characteristics with clinical outcomes were conducted, with data obtained between January 1, 2011, and January 1, 2018. Exposures: Tumor CGP, including presence of a driver alteration (a pathogenic or likely pathogenic alteration in a gene shown to drive tumor growth); tumor mutation burden (TMB), defined as the number of mutations per megabase; and clinical characteristics gathered from EHRs. Main Outcomes and Measures: Overall survival (OS), time receiving therapy, maximal therapy response (as documented by the treating physician in the EHR), and clinical benefit rate (fraction of patients with stable disease, partial response, or complete response) to therapy. Results: Among 4064 patients with NSCLC (median age, 66.0 years; 51.9% female), 3183 (78.3%) had a history of smoking, 3153 (77.6%) had nonsquamous cancer, and 871 (21.4%) had an alteration in EGFR, ALK, or ROS1 (701 [17.2%] with EGFR, 128 [3.1%] with ALK, and 42 [1.0%] with ROS1 alterations). There were 1946 deaths in 7 years. For patients with a driver alteration, improved OS was observed among those treated with (n = 575) vs not treated with (n = 560) targeted therapies (median, 18.6 months [95% CI, 15.2-21.7] vs 11.4 months [95% CI, 9.7-12.5] from advanced diagnosis; P < .001). TMB (in mutations/Mb) was significantly higher among smokers vs nonsmokers (8.7 [IQR, 4.4-14.8] vs 2.6 [IQR, 1.7-5.2]; P < .001) and significantly lower among patients with vs without an alteration in EGFR (3.5 [IQR, 1.76-6.1] vs 7.8 [IQR, 3.5-13.9]; P < .001), ALK (2.1 [IQR, 0.9-4.0] vs 7.0 [IQR, 3.5-13.0]; P < .001), RET (4.6 [IQR, 1.7-8.7] vs 7.0 [IQR, 2.6-13.0]; P = .004), or ROS1 (4.0 [IQR, 1.2-9.6] vs 7.0 [IQR, 2.6-13.0]; P = .03). In patients treated with anti-PD-1/PD-L1 therapies (n = 1290, 31.7%), TMB of 20 or more was significantly associated with improved OS from therapy initiation (16.8 months [95% CI, 11.6-24.9] vs 8.5 months [95% CI, 7.6-9.7]; P < .001), longer time receiving therapy (7.8 months [95% CI, 5.5-11.1] vs 3.3 months [95% CI, 2.8-3.7]; P < .001), and increased clinical benefit rate (80.7% vs 56.7%; P < .001) vs TMB less than 20. Conclusions and Relevance: Among patients with NSCLC included in a longitudinal database of clinical data linked to CGP results from routine care, exploratory analyses replicated previously described associations between clinical and genomic characteristics, between driver mutations and response to targeted therapy, and between TMB and response to immunotherapy. These findings demonstrate the feasibility of creating a clinicogenomic database derived from routine clinical experience and provide support for further research and discovery evaluating this approach in oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · cited 1×
“Tumormutational burden (TMB), ameasureof thenumberof somaticmutationsidentifiedpermegabaseofDNAsequenced,was calculated foreverypatient in thecohort.(10)Patientswerestratified intoTMB-high (TMB-H,≥20mutations/Mb)andTMB-low/ intermediate (TMB-L/I, <20mutations/Mb) based on prior efforts to define TMB cutoffs for respon…”
BackgroundSelf-citationZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“12 Specifically, 4 sources of data were combined to develop a death data set of high sensitivity and specificity relative to standard National Death Index data: (1) EHR structured data contained within the clinical database; (2) abstracted data from EHR unstructured documents (eg, end-of-treatment notes or condolence…”
MethodFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
Self-citationFrampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 1×
“7% of all samples; eTable 1 in the Supplement).(8)Pointmutations, amplifications, deletions, duplications, insertions, splice site variants, and rearrangements werecategorizedaseitherknownpathogenic, likelypathogenic, variantsofunknownsignificance,orgermlinesingle-nucleotide polymorphisms.”
BackgroundAACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Barlesi, F., Mazieres, J., Merlio, J.-P., Debieuvre, D., Mosser, J., Lena, H., Ouafik, L., Besse, B., Rouquette, I., Westeel, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00004-0 · Cited by 1,004
Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint
Curtis, M. D., Griffith, S. D., Tucker, M., Taylor, M. D., Capra, W. B., Carrigan, G., Holzman, B., Torres, A. Z., You, P., Arnieri, B., et al. (2018) · Health Services Research · doi:10.1111/1475-6773.12872 · Cited by 217
Self-citationVignot, S., Frampton, G. M., Soria, J.-C., Yelensky, R., Commo, F., Brambilla, C., Palmer, G., Moro-Sibilot, D., Ross, J. S., Cronin, M. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7737 · Cited by 175
Cited by
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Non‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · Cancer Communications · doi:10.1002/cac2.12359 · Cited by 656
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Bai, R., Lv, Z., Xu, D., & Cui, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00209-0 · Cited by 471
Systemic therapies for intrahepatic cholangiocarcinoma
Kelley, R. K., Bridgewater, J., Gores, G. J., & Zhu, A. X. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.009 · Cited by 412
Milbury, C. A., Creeden, J., Yip, W.-K., Smith, D. L., Pattani, V., Maxwell, K., Sawchyn, B., Gjoerup, O., Meng, W., Skoletsky, J., et al. (2022) · PLOS ONE · doi:10.1371/journal.pone.0264138 · Cited by 376
Self-citationMa, X., Long, L., Moon, S., Adamson, B. J. S., & Baxi, S. S. (2020) · medRxiv · doi:10.1101/2020.03.16.20037143 · Cited by 353
Evaluating eligibility criteria of oncology trials using real-world data and AI
Liu, R., Rizzo, S., Whipple, S., Pal, N., Pineda, A. L., Lu, M., Arnieri, B., Lu, Y., Capra, W., Copping, R., et al. (2021) · Nature · doi:10.1038/s41586-021-03430-5 · Cited by 322
Lee, J. K., Sivakumar, S., Schrock, A. B., Madison, R., Fabrizio, D., Gjoerup, O., Ross, J. S., Frampton, G. M., Napalkov, P., Montesion, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00334-z · Cited by 187
Self-citationAutomated Real-World Data Integration Improves Cancer Outcome Prediction
Jee, J., Fong, C., Pichotta, K., Tran, T. N., Luthra, A., Waters, M., Fu, C., Altoe, M., Liu, S.-Y., Maron, S. B., et al. (2024) · Nature · doi:10.1038/s41586-024-08167-5 · Cited by 188
Harnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125
Rolfo, C. D., Madison, R. W., Pasquina, L. W., Brown, D. W., Huang, Y., Hughes, J. D., Graf, R. P., Oxnard, G. R., & Husain, H. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3321 · Cited by 104
Choi, Y.-M., Lee, H., Ann, M., Song, M., Rheey, J., & Jang, J. (2023) · Biofabrication · doi:10.1088/1758-5090/acd95f · Cited by 94
“Thus, the chemotherapy regimen for most patients with LC depends on the molecular profiling of driver mutations [16].”
STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
Shire, N. J., Klein, A. B., Golozar, A., Collins, J. M., Fraeman, K. H., Nordstrom, B. L., McEwen, R., Hembrough, T., & Rizvi, N. A. (2020) · PLOS ONE · doi:10.1371/journal.pone.0238358 · Cited by 85
“The generation and validation of the Flatiron CGDB as well as methods for clinical data extraction, de-identification of patient data, linkage of the clinical and genomic data, and tumor genotyping (using the FoundationOne platform) have been described previously [35].”
BackgroundMethodResultInfluentialAnti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
Zhang, C., Fan, Y., Che, X., Zhang, M., Li, Z., Li, C., Wang, S., Wen, T., Hou, K., Shao, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00760 · Cited by 69
Fakih, M., Tu, H., Hsu, H., Aggarwal, S., Chan, E., Rehn, M., Chia, V., & Kopetz, S. (2022) · The Oncologist · doi:10.1093/oncolo/oyac077 · Cited by 43
Johnson, R. M., Qu, X., Lin, C.-F., Huw, L.-Y., Venkatanarayan, A., Sokol, E., Ou, F.-S., Ihuegbu, N., Zill, O. A., Kabbarah, O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33172-5 · Cited by 42
Sholl, L. M., Awad, M., Basu Roy, U., Beasley, M. B., Cartun, R. W., Hwang, D. M., Kalemkerian, G., Lopez-Rios, F., Mino-Kenudson, M., Paintal, A., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0536-cp · Cited by 38
Julian, C., Pal, N., Gershon, A., Evangelista, M., Purkey, H., Lambert, P., Shi, Z., & Zhang, Q. (2023) · BMC Cancer · doi:10.1186/s12885-023-10778-6 · Cited by 31
Choi, Y., Dharia, N. V., Jun, T., Chang, J., Royer-Joo, S., Yau, K. K., Assaf, Z. J., Aimi, J., Sivakumar, S., Montesion, M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0255 · Cited by 23
Metadata
- Authors
- Singal, G., Miller, P. G., Agarwala, V., Li, G., Kaushik, G., Backenroth, D., Gossai, A., Frampton, G. M., Torres, A. Z., Lehnert, E. M., Bourque, D., O’Connell, C., Bowser, B., Caron, T., Baydur, E., Seidl-Rathkopf, K., Ivanov, I., Alpha-Cobb, G., Guria, A., He, J., Frank, S., Nunnally, A. C., Bailey, M., Jaskiw, A., Feuchtbaum, D., Nussbaum, N., Abernethy, A. P., & Miller, V. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2019-04-09
- Volume
- 321
- Issue
- 14
- Pages
- 1391
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2938929416
- Cited by
- 549
- References
- 12
- FWCI
- 47.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.